GenSight Biologics S.A. (EPA:SIGHT)
France · Delayed Price · Currency is EUR 0.0885
+0.0018 (2.08%)
Apr 2, 2026, 5:35 PM CET
GenSight Biologics Revenue
In the year 2025, GenSight Biologics had annual revenue of 652.00K EUR, down -75.16%. GenSight Biologics had revenue of 604.00K in the half year ending December 31, 2025, with 143.55% growth.
Revenue
652.00K
Revenue Growth
-75.16%
P/S Ratio
31.85
Revenue / Employee
50.15K
Employees
13
Market Cap
20.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 652.00K | -1.97M | -75.16% |
| Dec 31, 2024 | 2.63M | -339.00K | -11.44% |
| Dec 31, 2023 | 2.96M | -1.90M | -39.08% |
| Dec 31, 2022 | 4.87M | -2.84M | -36.89% |
| Dec 31, 2021 | 7.71M | 269.00K | 3.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| genOway Société anonyme | 27.16M |
| Fermentalg | 12.78M |
| Poxel | 7.66M |
| Advicenne | 5.90M |
| Nicox | 3.32M |
| Aelis Farma | 2.33M |
| Plant Advanced Technologies | 2.22M |
| Valerio Therapeutics Société anonyme | 1.83M |
GenSight Biologics News
- 20 hours ago - GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates - Business Wire
- 8 days ago - GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025 - Business Wire
- 15 days ago - The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ® - Business Wire
- 26 days ago - GenSight Biologics Provides Updates about GS010/LUMEVOQ® Early Access Programs and the Ongoing REVISE Study - Business Wire
- 6 weeks ago - GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Business Wire
- 7 weeks ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire
- 2 months ago - GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - Business Wire
- 3 months ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire